Patents Issued in January 12, 2010
-
Patent number: 7645741Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.Type: GrantFiled: November 1, 2007Date of Patent: January 12, 2010Assignee: Aegera Therapeutics, Inc.Inventors: Alain Boudreault, James B. Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
-
Patent number: 7645742Abstract: A composition for enhancing cellular energy that includes creatine, L-arginine-?-ketoglutarate, D-ribose, L-carnitine, L-citrulline, and pyruvate. The composition is administering to a subject to enhance cellular energy, to increase relative intensity of physical activity performed by the subject, to increase endurance of the subject during the physical activity and to increase the muscle mass of the subject.Type: GrantFiled: June 22, 2005Date of Patent: January 12, 2010Assignee: Advocare International, L.P.Inventor: Sidney Stohs
-
Patent number: 7645743Abstract: Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target.Type: GrantFiled: January 9, 2004Date of Patent: January 12, 2010Assignee: Altermune, LLCInventor: Kary B. Mullis
-
Patent number: 7645744Abstract: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in particularly in diseases such as diabetic retinopathy, age related macular degeneration and many types of cancer.Type: GrantFiled: January 26, 2009Date of Patent: January 12, 2010Assignee: The Trustees of the University of PennsylvaniaInventors: Samuel Jotham Reich, Enrico Maria Surace, Michael J. Tolentino
-
Patent number: 7645745Abstract: Compounds having the formula I wherein R1 is as herein defined are Hepatitis C virus NS5b polymerase inhibitors.Type: GrantFiled: April 4, 2007Date of Patent: January 12, 2010Assignee: Roche Palo Alto LLCInventor: Keshab Sarma
-
Patent number: 7645746Abstract: The present invention relates to an aqueous composition for reducing malodor impression. The composition comprises from about 0.01% to about 1%, by weight of the composition, of perfume. Optionally, but preferably, the composition comprises from about 0.1% to about 5%, by weight of the composition of, water-soluble cyclodextrin, from about 0.1% to about 10%, by weight of the composition, of water-soluble metallic salt, from about 0% to about 3%, by weight of the composition, of solubilizing aid. The composition is essentially free of any material that would soil or stain fabric and contains less than about 5%, by weight of the composition of low molecular weight monohydric alcohols.Type: GrantFiled: November 13, 2000Date of Patent: January 12, 2010Assignee: The Procter & Gamble CompanyInventors: Toan Trinh, Jerome Paul Cappel, Philip Anthony Geis, Judith Ann Hollingshead, Mark Lee McCarty, Donald Marion Swartley, Errol Hoffman Wahl, Susan Schmaedecke Zwerdling
-
Patent number: 7645747Abstract: The invention is related to phosphorus substituted therapeutic agents, compositions containing such phosphorus substituted agents, and therapeutic methods that include the administration of such phosphorus substituted agents, as well as to processes and intermediates useful for preparing such agents.Type: GrantFiled: October 25, 2005Date of Patent: January 12, 2010Assignee: Gilead Sciences, Inc.Inventors: Constantine G. Boojamra, Carina E. Cannizzaro, James M. Chen, Xiaowu Chen, Aesop Cho, Lee S. Chong, Manoj Desai, Maria Fardis, Craig S. Gibbs, Ralph F. Hirschmann, Alan X. Huang, Haolun Jin, Choung U. Kim, Thorsten A. Kirschberg, Steven Krawczyk, Christopher P. Lee, William A. Lee, Kuei-Ying Lin, Richard L. Mackman, David Y. Markevitch, Peter H. Nelson, David A. Oare, Vidya K. Prasad, Hyung-Jung Pyun, Adrian S. Ray, Rosemarie Sherlock, Sundaramoorthi Swaminathan, William J. Watkins, Jennifer R. Zhang, Lijun Zhang
-
Patent number: 7645748Abstract: Sterol and stanol phosphorylnitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed compounds include a phosphate linker, at least one moiety that releases nitric oxide (NO), and a sterol or stanol moiety. Some compounds additionally include an ascorbyl moiety to make the compound more readily soluble in aqueous and non-aqueous media.Type: GrantFiled: April 3, 2006Date of Patent: January 12, 2010Assignee: Forbes Medi-Tech Inc.Inventors: Patricia Liliana Orchansky, James P. Kutney
-
Patent number: 7645749Abstract: Sterol and stanol nitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed nitro derivatives are synthesized by ester linkage of a nitric oxide (NO)-releasing moiety to a sterol or stanol compound.Type: GrantFiled: April 3, 2006Date of Patent: January 12, 2010Assignee: Forbes Medi-Tech Inc.Inventors: Patricia Liliana Orchansky, James P. Kutney
-
Patent number: 7645750Abstract: A method for treating or preventing symptoms of hormonal variation includes administering an effective amount of a receptor antagonist to a subject having one or more symptoms of hormonal variations, wherein the receptor antagonist binds to at least one selected from the group consisting of a serotonin type 2A (5-HT2A) and a dopamine type 2 (D2) receptors.Type: GrantFiled: December 13, 2006Date of Patent: January 12, 2010Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventor: Hung-Ming Wu
-
Patent number: 7645751Abstract: There is provided a compound of formula (I) wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically-acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g., thrombosis) or as anticoagulants.Type: GrantFiled: May 4, 2007Date of Patent: January 12, 2010Assignee: AstraZenecaInventor: Tord Inghardt
-
Patent number: 7645752Abstract: The present invention is directed to compounds of Formula I: which are modulators of the 5-hydroxtryptamine-6 and 5-hydroxytryptamine-2A receptors and which are inhibitors of norepinephrine reuptake. The compounds of the invention, and pharmaceutical composition thereof, are useful in the treatment of disorders related to or associated with the 5-hydroxytryptamine-6 and 5-hydroxtryptamine-2A receptors or with norepinephrine reuptake inhibition.Type: GrantFiled: January 12, 2007Date of Patent: January 12, 2010Assignee: Wyeth LLCInventors: Robert E. McDevitt, Yanfang Li, Albert J. Robichaud, Gavin D. Heffernan, Richard D. Coghlan, Ronald C. Bernotas
-
Patent number: 7645753Abstract: This invention is concerned with compounds of the formula wherein A, B1, B2, R1, R2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.Type: GrantFiled: March 2, 2006Date of Patent: January 12, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Andreas Dominik Christ, Luke Gideon Granville Green, Wolfgang Guba, Hans-Peter Maerki, Rainer Eugen Martin, Peter Mohr
-
Patent number: 7645754Abstract: The subject invention provides compounds having the structure: wherein, R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(?O)NRaRb, —NRaRb, —NRaC(?O)NRaRb, —NRaC(?O)ORa, —OC(?O)NRaRb, or —NHC(?O) Ra; R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(?O)NRaRb, —NRaRb, —NRaC(?O)NRaRb, —NRaC(?O)ORa, —OC(?O)NRaRb, or —NHC(?O)Ra, or R1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(?O)OH; R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb; R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl; R5 is —(CH2)mOR6, —CHNOR7, —C(?O)NR8R9, —(CH2)mC(?O)OR10, —(CH2)kC(?O)NR11R12; wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroarylType: GrantFiled: June 19, 2007Date of Patent: January 12, 2010Assignee: OSI Pharmaceuticals, Inc.Inventors: Arlindo Castelhano, Bryan McKibben, Arno Steinig
-
Patent number: 7645755Abstract: The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.Type: GrantFiled: April 20, 2006Date of Patent: January 12, 2010Assignee: Janssen Pharmaceutical N.V.Inventors: Carl R. Illig, Shelley K. Ballentine, Jinsheng Chen, Sanath K. Meegalla, M. Jonathan Rudolph, Mark J. Wall, Kenneth J. Wilson, Renee L. Desjarlais, Carl L. Manthey, Christopher Flores, Christopher J. Molloy
-
Patent number: 7645756Abstract: The invention provides a compound or its pharmaceutically-acceptable salt of formula wherein A1 is a hydrogen, etc.; j and k are 0 or 1; is a double bond, etc.; is a double bond, etc.; one of W1 and W2 is E—O—W, etc., and the other is a hydrogen atom, etc.; E is a divalent group derived from a benzene ring, etc., by removing two hydrogen atoms therefrom; W is a group of formula (II-1): which has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for prevention or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.Type: GrantFiled: February 17, 2005Date of Patent: January 12, 2010Assignee: Banyu Pharmaceutical Co. Ltd.Inventors: Toshiyuki Takahashi, Akio Kanatani, Shigeru Tokita, Ryo Yoshimoto
-
Patent number: 7645757Abstract: The present invention is directed to compounds and compositions for the treatment of neurological diseases that cause neurogenic and neuropathic pain, inflammatory diseases, renal ishaemia, cardiovascular disease and other pathologies caused by the presence of endogenous cannabinoids and or other substrates resulting from the metabolic activities of fatty acid amido hydrolase (FAAH). These compounds are represented by the formula alkylene group; a salt thereof, or a hydrate or a solvate of said compound or said salt; where the variables are as defined in the attached specification.Type: GrantFiled: August 14, 2006Date of Patent: January 12, 2010Assignee: sanofi-aventisInventors: Ahmed Abouabdellah, Regine Bartsch-Li, Christian Hoornaert, Antoine Ravet
-
Patent number: 7645758Abstract: Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis.Type: GrantFiled: April 13, 2007Date of Patent: January 12, 2010Assignee: Janssen Pharmaceutica, N.Y.Inventors: Hui Cai, Nicholas I. Carruthers, Curt A. Dvorak, James P. Edwards, Annette K. Kwok, Jianmei Wei
-
Patent number: 7645759Abstract: Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a —NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a —NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.Type: GrantFiled: April 10, 2007Date of Patent: January 12, 2010Assignee: Istituto Luso Farmaco D'Italia S.p.A.Inventors: Patrizia Felicetti, Christopher Ingo Fincham, Alessandro Giolitti, Carlo Alberto Maggi, Laura Quartara, Cristina Rossi
-
Patent number: 7645760Abstract: A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.Type: GrantFiled: October 24, 2003Date of Patent: January 12, 2010Assignee: Novartis AG.Inventors: Birgit Bollbuck, Jorg Eder, Richard Heng, Laszio Revesz, Achim Schlapbach, Rudolf Walchli
-
Patent number: 7645761Abstract: This invention relates to substituted indoline derivative compounds which are antagonists of the progesterone receptor, their preparation and pharmaceutical utility, particularly including contraception and treatment of benign or malignant neoplastic diseases, having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic rings.Type: GrantFiled: June 22, 2007Date of Patent: January 12, 2010Assignee: WyethInventors: Andrew Fensome, Lori L. Miller, John W. Ullrich, Reinhold H. W. Bender, Puwen Zhang, Jay E. Wrobel, Lin Zhi, Todd K. Jones, James P. Edwards, Christopher M. Tegley
-
Patent number: 7645762Abstract: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.Type: GrantFiled: October 4, 2006Date of Patent: January 12, 2010Assignee: Schering CorporationInventors: Kamil Paruch, Timothy J. Guzi, Michael P. Dwyer
-
Patent number: 7645763Abstract: The present invention relates to substituted xanthines of general formula wherein R1 and R2 are defined as in the claims, the tautomers, the stereoisomers, the mixtures thereof, and the salts thereof, which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).Type: GrantFiled: February 22, 2005Date of Patent: January 12, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Mohammad Tadayyon, Leo Thomas
-
Patent number: 7645764Abstract: Compounds of formula I: wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds, pharmaceutical compositions, methods of using the compounds for treatment of p38 MAP kinase-mediated diseases, and methods of using the compounds for treatment of Raf kinase-mediated diseases.Type: GrantFiled: November 8, 2007Date of Patent: January 12, 2010Assignee: Roche Palo Alto LLCInventors: Tobias Gabriel, Joel McIntosh, Kin-Chun Thomas Luk
-
Patent number: 7645765Abstract: The invention relates to a drug containing an aqueous formulation of Moxaverin and at least one water-miscible solubilizer.Type: GrantFiled: September 2, 2002Date of Patent: January 12, 2010Assignee: Molecular and Clinical Drug ResearchInventor: Ralph E. Eckert
-
Patent number: 7645766Abstract: A method for treatment of depression and depressive mood disorders. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A, so as to increase synaptic metabolism of serotonin to 5-HIAL. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. A caffeine compound may be administered simultaneously so as to compensate for an antihypertensive effect of the reserpine. The caffeine compound may be combined with the reserpine in a transdermal cream.Type: GrantFiled: September 20, 2005Date of Patent: January 12, 2010Assignee: MedDEV, Inc.Inventor: Elaine A. Delack
-
Patent number: 7645767Abstract: Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a ?-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.Type: GrantFiled: August 22, 2007Date of Patent: January 12, 2010Assignee: Trinity Laboratories, Inc.Inventors: Chandra Ulagaraj Singh, David Lloyd Woody, Jagaveerabhadra Rao Nulu
-
Patent number: 7645768Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).Type: GrantFiled: July 16, 2007Date of Patent: January 12, 2010Assignee: WyethInventors: Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven Moss
-
Patent number: 7645769Abstract: The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.Type: GrantFiled: August 4, 2006Date of Patent: January 12, 2010Assignee: Eisai R & D Management Co., Ltd.Inventors: Afzal Khan, Darren Peter Medland, Gurpreet Singh Bhatia
-
Patent number: 7645770Abstract: Phenylalanine enamide derivatives of formula (1) are described: wherein R1 is a group Ar1L2Ar2Alk- in which: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a covalent bond or a linker atom or group; Ar2 is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH2—CH(R)—, —CH?C(R)— or in which R is a carboxylic acid (—CO2H) or a derivative or biostere thereof; X is an —O— or —S— atom or —N(R2)— group in which: Rx, Ry and Rz which may be the same or different is each a hydrogen atom or an optional substituent; or Rz is an atom or group as previously defined and Rx and Ry are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof.Type: GrantFiled: December 3, 2008Date of Patent: January 12, 2010Assignee: UCB Pharma S.A.Inventors: Stephen Brand, Stuart Bailey, Julien A. Brown, James A. Johnson, John R. Porter, John C. Head
-
Patent number: 7645771Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).Type: GrantFiled: December 12, 2003Date of Patent: January 12, 2010Assignee: SmithKline Beecham Corp.Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
-
Patent number: 7645772Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: October 28, 2003Date of Patent: January 12, 2010Assignee: Wellstat Therapeutics CorporationInventors: Kirvin L. Hodge, Shalini Sharma, Reid W. von Borstel, Stephen D. Wolpe
-
Patent number: 7645773Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.Type: GrantFiled: January 8, 2007Date of Patent: January 12, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Paul Gillespie, Robert Alan Goodnow, Jr., Agnieszka Kowalczyk, Kang Le, Qiang Zhang
-
Patent number: 7645774Abstract: There are disclosed compounds of the formula I: or a pharmaceutically acceptable salt of the compound, which exhibit anti-inflammatory and immunomodulatory activity. Also disclosed are pharmaceutical compositions containing said compounds.Type: GrantFiled: August 5, 2005Date of Patent: January 12, 2010Assignee: Schering CorporationInventors: Richard J. Friary, Joseph A. Kozlowski, Bandarpalle B. Shankar, Michael K. C. Wong, Guowei Zhou, Brian J. Lavey, Neng-Yang Shih, Ling Tong, Lei Chen, Youheng Shu
-
Patent number: 7645775Abstract: The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: October 21, 2005Date of Patent: January 12, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Davies, Cornelia Forster, Michael Arnost, Jian Wang
-
Patent number: 7645776Abstract: The invention is concerned with novel substituted piperidine derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.Type: GrantFiled: November 29, 2006Date of Patent: January 12, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Jean Ackermann, Konrad Bleicher, Simona M. Ceccarelli Grenz, Odile Chomienne, Patrizio Mattei, Tanja Schulz-Gasch
-
Patent number: 7645777Abstract: A switching device is discloses that exhibits two stable resistance values to a voltage applied between electrodes. The switching device comprises thin films of a first electrode layer, an organic bistable material layer and a second electrode layer sequentially formed on a substrate, and the organic bistable material is a specified quinone compound.Type: GrantFiled: November 20, 2006Date of Patent: January 12, 2010Assignee: Fuji Electric Holdings Co., Ltd.Inventors: Nobuyuki Sekine, Haruo Kawakami, Hisato Kato, Keisuke Yamashiro, Kyoko Kato, Masami Kuroda
-
Patent number: 7645778Abstract: The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.Type: GrantFiled: January 17, 2006Date of Patent: January 12, 2010Assignee: Bristol-Myers Squibb COmpanyInventors: James C. Sutton, Zulan Pi, Rejean Ruel, Alexandre L'Heureux, Carl Thibault, Patrick Y. S. Lam
-
Patent number: 7645779Abstract: Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.Type: GrantFiled: August 20, 2004Date of Patent: January 12, 2010Assignees: Amgen Inc., Japan Tobacco, Inc.Inventors: Hiroyuki Abe, Jonathan Houze, Hisashi Kawasaki, Frank Kayser, Rajiv Sharma, Samuel Sperry
-
Patent number: 7645780Abstract: Disclosed are compounds of the formula: where variables Z, X, R15, R2, R3, and Rc are defined herein. Compounds disclosed herein are inhibitors of the beta-secretase enzyme and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal.Type: GrantFiled: June 6, 2006Date of Patent: January 12, 2010Assignee: Elan Pharmaceuticals, Inc.Inventors: Varghese John, Michel Maillard, James P. Beck, Eric T. Baldwin, Robert Hughes, Shon R. Pulley, Ruth T. TenBrink
-
Patent number: 7645781Abstract: The present invention provides antibacterial agents having the formulae I, II, and III described herein.Type: GrantFiled: September 21, 2006Date of Patent: January 12, 2010Assignee: Pfizer IncInventors: Richard C. Thomas, Toni-Jo Poel, Michael R. Barbachyn, Mikhail F. Gordeev, Gary W. Luehr, Adam Renslo, Upinder Singh, Vara Prasad Venkata Negandra Josyula
-
Patent number: 7645782Abstract: The present invention relates to new Macrocycles of formula (I) and their use for the treatment of cancer.Type: GrantFiled: November 28, 2003Date of Patent: January 12, 2010Assignees: Morphochem Aktiengesellschaft fur Kombinatorische ChemieInventors: Wolfgang Richter, Lutz Weber
-
Patent number: 7645783Abstract: A method of treating viral infections by the administration of a halogenated benzamide derivative according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.Type: GrantFiled: October 1, 2007Date of Patent: January 12, 2010Assignee: Romark Laboratories L.C.Inventor: Jean Francois Rossignol
-
Patent number: 7645784Abstract: Compounds of formula I, wherein R1, m, R2, R3, p, n, R5 and R9 are as defined as in the specification, salts, solvates or solvated salts thereof, processes for their preparation, intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and the use of said compounds in therapy.Type: GrantFiled: May 13, 2004Date of Patent: January 12, 2010Assignee: AstraZeneca ABInventors: Yevgeni Besidski, Inger Kers, Martin Nylöf, Didier Rotticci, Andis Slaitas, Mats Svensson
-
Patent number: 7645785Abstract: The invention is concerned with novel benzimidazole derivatives of formula (I) wherein R1 to R8 are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.Type: GrantFiled: June 22, 2007Date of Patent: January 12, 2010Assignee: Hoffmann-La Roche Inc.Inventors: Gregory Martin Benson, Konrad Bleicher, Alexander Chucholowski, Henrietta Dehmlow, Uwe Grether, Bernd Kuhn, Rainer E. Martin, Eric J. Niesor, Narendra Panday, Hans Richter, Franz Schuler, Xavier Marie Warot, Matthew Wright, Minmin Yang
-
Patent number: 7645786Abstract: This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.Type: GrantFiled: December 14, 2006Date of Patent: January 12, 2010Assignee: Pfizer Inc.Inventors: Denis Billen, Jessica Boyle, Douglas James Critcher, David Morris Gethin, Kim Thomas Hall, Graham Michael Kyne
-
Patent number: 7645787Abstract: The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.Type: GrantFiled: July 6, 2007Date of Patent: January 12, 2010Assignee: Ajinomoto Co., Inc.Inventors: Koji Ohsumi, Takashi Umemura, Hiroyuki Matsueda, Toshihiro Hatanaka, Akiko Onuki, Katsumi Maezono, Yoko Kageyama, Nobuo Kondo
-
Patent number: 7645788Abstract: Use of the tetramerous derivative of indole-3-carbinol having formula I for preparing a medicinal having anti-carcinogenic activity, and method of synthesis of the tetramerous derivative having formula I, in which indole-3-carbinol is reacted with an oxidizing agent so as to cause a polymeric oxidation of indole-3-carbinol.Type: GrantFiled: June 5, 2002Date of Patent: January 12, 2010Assignee: Universita' Degli Studi Di UrbinoInventors: Mauro Magnani, Chiara Fiorucci, Paolino Filippone, Giorgio Brandi, Mirko Paiardini
-
Patent number: 7645789Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.Type: GrantFiled: October 18, 2007Date of Patent: January 12, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Sara S. Hadida Ruah, Peter D. J. Grootenhuis, Fredrick Van Goor, Jinglan Zhou, Brian Bear, Mark T. Miller, Jason McCartney, Mehdi Michel Djamel Numa
-
Patent number: 7645790Abstract: The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.Type: GrantFiled: January 26, 2005Date of Patent: January 12, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Jaime Lynn Bunda, Robert J. DeVita, Jinlong Jiang, Sander G. Mills